WST — West Pharmaceutical Services Income Statement
0.000.00%
Last trade - 00:00
- $21.81bn
- $21.57bn
- $2.95bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,840 | 2,147 | 2,832 | 2,887 | 2,950 |
Cost of Revenue | |||||
Gross Profit | 606 | 768 | 1,178 | 1,136 | 1,129 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,543 | 1,740 | 2,081 | 2,205 | 2,270 |
Operating Profit | 297 | 407 | 751 | 682 | 680 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 292 | 401 | 749 | 680 | 698 |
Provision for Income Taxes | |||||
Net Income After Taxes | 233 | 329 | 640 | 560 | 576 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 242 | 346 | 662 | 586 | 593 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 242 | 346 | 662 | 586 | 593 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.27 | 4.7 | 8.75 | 8.4 | 8.15 |
Dividends per Share |